New antidepressive drug.
|
Accession number;99A0526252
|
| Title;New antidepressive drug. |
| Author;
KUDO YOSHIO
(Asakayama Hosp.)
KUDO TAKASHI
(Osaka Univ., Grad. Sch.)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.15;NO.5;PAGE.711-723(1999)
|
| Figure&Table&Reference;FIG.10, REF.19 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The first type of new antidepressants is selective serotonin reuptake inhibitors(SSRI). SSRIs inhibit the presynaptic reuptake of serotonin, and increase serotonin concentration in the synaptic cleft, thus improving depressive symptoms caused by hypoactivity resulting from lowered serotonin in the central nervous system. Drugs with this type of action include fluvoxamine, sertraline, and paroxetine, and are characterized by antidepressive effects comparable to those of tricyclic antidepressants, but with lower frequency of anticholenasic or cardiotoxic effects. The second type is serotonin norepinephrin reuptake inhibitors(SNRI) which inhibit the reuptake of norepinephrin and serotonin in the central nervous system. SNRI increase norepinephrin and serotonin levels in the synaptic cleft, resulting in an antidepressant effect. Drugs acting in this way include milnacipran, duloxetine(LY248086), and MCI-225. These drugs also have antidepressive effects comparable to those of tricyclic antidepressants, but with lower frequency of anticholenasic or cardiotoxic effects. The third type is drugs which work as serotonin receptor antagonists and inhibit serotonin reuptake. These drugs include nefazodone(BMY13754). They have comparable utility to SSRI. The fourth type is serotonin1A antagonists, such as MKC-242 and SOL102. These drugs also have comparable utility to SSRI. The fifth type is reversible inhibitors of MAO(RIMA), such as moclobemide(RO-11). They have typical antidepressive effects, but with lower liver toxicity. (author abst.) |
|
|
|
Related Articles;
|
|
